

DAFTAR PUSTAKA

- Adunlin, G., Skiera, J., Cupp, C. S., Ali, A. A., & Afeli, S. A. Y. (2023). The state of pharmacoeconomics education in the Doctor of Pharmacy curriculum amid the changing face of pharmacy practice. *Advances in Medical Education and Practice*, 14, 1237–1245. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10671399/>
- Aisyah, N., Saputra, Y., & Mardiana. (2019). Komparasi biaya medis langsung dengan tarif INA-CBG's pada pasien rawat inap kemoterapi kanker paru di RSUD Ulin Banjarmasin. *Jurnal Insan Farmasi Indonesia*, 2(2), 212–221.
- Alaydrus, N. (2020). Analisis selisih biaya medis langsung dengan klaim INA CBGs pada pasien penyakit jantung di RSUP Dr. Wahidin Sudirohusodo Makassar. *Tesis, Universitas Hasanuddin*. <http://digilib.unhas.ac.id>
- Amalia, R. (2020). *Analisis kesesuaian biaya medis langsung pelayanan dengan tarif INA-CBGs pada pasien rawat inap di RSUD dr. Saiful Anwar Malang*.
- American Cancer Society. (2024). *Lung cancer early detection, diagnosis, and staging*. American Cancer Society.
- Ananthapavan, J., Moodie, M., Milat, A., et al. (2021). A cost–benefit analysis framework for preventive health interventions to aid decision-making in Australian governments. *Health Research Policy and Systems*, 19, 147. <https://doi.org/10.1186/s12961-021-00796-w>
- Andrajati, R., Thobary, J. A., Setiawan, D., Herawati, F., Endarti, D., Anggriani, Y., Rahman, H. A., Hermawan, H., Yettyningsih, Y., Yeni, P., Prihayati, A., Astuti, R., & Erinsyah, W. L. (2024). *E-book farmakoekonomi*. Malang: Future Science.
- Andriani, Y., Kristina, S. A., & Wiedyaningsih, C. (2019). Estimasi biaya pengobatan langsung penyakit kanker di Indonesia: Estimasi direct medical cost (DMC). *Majalah Farmaseutik*, 17(3), 251–255. <https://jurnal.ugm.ac.id/majalahfarmaseutik/article/view/49823/33937>
- Bade, B. C., & Dela Cruz, C. S. (2020). Lung cancer 2020: Epidemiology, etiology, and prevention. *Clinics in Chest Medicine*, 41(1), 1–24. <https://doi.org/10.1016/j.ccm.2019.10.001>
- Biomarker Research. (2024). Oncogenic alterations in advanced NSCLC: A molecular super-highway. *Biomarker Research*, 12, Article 24. <https://doi.org/10.1186/s40364-024-00566-0>
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6), 394–424. <https://doi.org/10.3322/caac.21492>
- Burr, M. L., Campbell, J. D., He, Y., Adoue, V., Brennan, P., Howarth, K., Swanton, C. (2024). Developmental mosaicism underlying EGFR-mutant lung cancer. *Nature Cancer*, 5(2), 210–222. <https://doi.org/10.1038/s43018-024-00840-y>

- Busse, R., Geissler, A., Quentin, W., Wiley, M., Cots, F., Häkkinen, U., Kobel, C., Mateus, C., Or, Z., O'Reilly, J., Serdén, L., Street, A., & Quentin, W. (2013). Diagnosis related groups in Europe: Moving towards transparency, efficiency, and quality in hospitals? *BMJ*, 346, f3197. <https://doi.org/10.1136/bmj.f3197>
- Chen, Y. (2021). Health technology assessment and economic evaluation: Is it applicable for the traditional medicine? *Integrative Medicine Research*, 10(3), 100756. <https://doi.org/10.1016/j.imr.2021.100756>
- China National Lung Cancer Screening Program. (2022). Sex disparity of lung cancer risk in non-smokers: A multicenter population-based prospective study. *Chinese Medical Journal*, 135(5), 584–595. <https://doi.org/10.1097/CM9.0000000000002161>
- Cicin, I., Oksuz, E., Karadurmus, N., Malhan, S., Gumus, M., Yilmaz, U., Cansever, L., Cinarka, H., Cetinkaya, E., Kiyik, M., Ozet, A., & Lung Cancer Report Study Group Turkey. (2021). Economic burden of lung cancer in Turkey: A cost of illness study from payer perspective. *Health Economics Review*, 11, 22. <https://doi.org/10.1186/s13561-021-00322-2>
- Criss, S. D., Palazzo, L., Watson, T. R., Paquette, A. M., Sigel, K., Wisnivesky, J., & Kong, C. Y. (2020). Cost-effectiveness of pembrolizumab for Advanced non-small cell lung cancer patients with varying comorbidity burden. *PLOS ONE*, 15(1), e0228288. <https://doi.org/10.1371/journal.pone.0228288>
- Detterbeck, F. C., Boffa, D. J., Kim, A. W., & Tanoue, L. T. (2017). The eighth edition lung cancer stage classification. *Chest*, 151(1), 193–203. <https://doi.org/10.1016/j.chest.2016.10.010>
- de Alencar, V. T. L., Formiga, M. N., Mesquita, R. D., & de Carvalho, M. B. (2020). Inherited lung cancer: A review. *Translational Lung Cancer Research*, 9(6), 2544–2558. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7039693/pdf/can-14-1008.pdf>
- de Groot, P. M., Wu, C. C., Carter, B. W., & Munden, R. F. (2018). The epidemiology of lung cancer. *Translational Lung Cancer Research*, 7(3), 220–233. <https://doi.org/10.21037/tlcr.2018.05.06>
- de Magalhães, J. P. (2013). How ageing processes influence cancer. *Nature Reviews Cancer*, 13(5), 357–365. <https://doi.org/10.1038/nrc3497>
- de Man, Y., Atsma, F., Oosterveld-Vlug, M. G., Brom, L., Onwuteaka-Philipsen, B. D., Westert, G. P., & Groenewoud, A. S. (2019). The Intensity of Hospital Care Utilization by Dutch Patients With Lung or Colorectal Cancer in their Final Months of Life. *Cancer Control*, 26(1), 1–9. <https://doi.org/10.1177/1073274819846574>
- Dietel, M., Bubendorf, L., Dingemans, A. M. C., Doms, C., Elmberger, G., García, R. C., Kerr, K. M., Lim, E., López-Ríos, F., Thunnissen, E., Van Schil, P. E., & von Laffert, M. (2016). Diagnostic procedures for non-small-cell lung cancer (NSCLC): Recommendations of the European Expert Group. *Thorax*, 71(2), 177–184. <https://doi.org/10.1136/thoraxjnl-2014-206677>

- Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). *Methods for the economic evaluation of health care programmes* (4th ed.). Oxford University Press.
- Duma, N., Santana-Davila, R., & Molina, J. R. (2019). Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. *Mayo Clinic Proceedings*, 94(8), 1623–1640. <https://doi.org/10.1016/j.mayocp.2019.01.013>
- Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I., & Bray, F. (2024). Global Cancer Observatory: Cancer Today (GLOBOCAN 2022, version 1.1). *International Agency for Research on Cancer*. <https://gco.iarc.who.int/today>
- Hadiningsih, H. (2015). Analisis Besaran Biaya Obat Beberapa Penyakit Rawat Jalan dan Faktor-Faktor yang Mempengaruhi di Rs. Awal Bros Bekasi Tahun 2014. *Jurnal Administrasi Rumah Sakit Indonesia*, 2(1), 53–63. <https://doi.org/10.7454/arsi.v2i1.2188>
- Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. *Nature*, 553(7689), 446–454. <https://doi.org/10.1038/nature25183>
- Hsu, K.-H., Tseng, J.-S., Wang, C.-L., Yang, T.-Y., Tseng, C.-H., Chen, H.-Y., Chen, K.-C., Tsai, C.-R., Yang, C.-T., Yu, S.-L., Su, K.-Y., Yu, C.-J., Ho, C.-C., Hsia, T.-C., Wu, M.-F., Chiu, K.-L., Liu, C.-M., Yang, P.-C., Chen, J. J. W., & Chang, G.-C. (2016). Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients. *Oncotarget*, 7(33), 53299–53308. <https://doi.org/10.18632/oncotarget.10715>
- Huang, F., dkk. (2017). Relationship between exposure to PM2.5 and lung cancer incidence and mortality: a meta-analysis. *Environmental Research*. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522148/>
- Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025). Advances in molecular pathology and therapy of non-small cell lung cancer. *Signal Transduction and Targeted Therapy*, 10(1), Article 186. <https://doi.org/10.1038/s41392-025-02243-6>
- Husereau, D., Drummond, M., Augustovski, F., Pwu, R.-F., Staniszewska, S., & CHEERS 2022 ISPOR Good Research Practices Task Force. (2022). Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. *Value in Health*, 25(1), 3–9. [https://www.valueinhealthjournal.com/article/S1098-3015\(21\)03146-6/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301521031466%3Fshowall%3Dtrue](https://www.valueinhealthjournal.com/article/S1098-3015(21)03146-6/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301521031466%3Fshowall%3Dtrue)
- Kementerian Kesehatan Republik Indonesia. (2023). *Pedoman Nasional Pelayanan Kedokteran (PNPK) Kanker Paru*. Jakarta: Kementerian Kesehatan Republik Indonesia. <https://yankes.kemkes.go.id>
- Kementerian Kesehatan Republik Indonesia. (2016). *Peraturan Menteri Kesehatan Nomor 76 Tahun 2016 tentang Pedoman Indonesian Case Base Groups*

- (INA-CBGs) dalam Pelaksanaan Jaminan Kesehatan Nasional. Jakarta: Kementerian Kesehatan RI.
- Kerr, K. M., Bibeau, F., Thunnissen, E., Botling, J., Ryška, A., Wolf, J., Öhrling, K., Burdon, P., Malapelle, U., & Büttner, R. (2021). The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. *Lung Cancer*, 154, 161–175. <https://doi.org/10.1016/j.lungcan.2021.02.026>
- Komite Penanggulangan Kanker Nasional. (2018). *Pedoman nasional pelayanan kedokteran: Kanker paru*. Jakarta: Kementerian Kesehatan Republik Indonesia. <http://61.8.75.226/itblog/attachments/article/1513/PNPKParu.pdf>
- Krstić, G. (2017). Radon versus other lung cancer risk factors. *Journal of the Air & Waste Management Association*. <https://doi.org/10.1080/10962247.2016.1240725>
- Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., Kwiatkowski, D. J., Ladanyi, M., Nowak, J. A., Sholl, L. M., Temple Smolkin, R. L., Solomon, B., Souter, L. H., Thunnissen, E., Tsao, M. S., & Wynes, M. W. (2018). Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. *Archives of Pathology & Laboratory Medicine*, 142(3), 321–346. <https://doi.org/10.5858/arpa.2017-0388-CP>
- Mahardika, I. G. A. P. D., Nita, Y., & Priyandani, Y. (2024). A comparative study of real hospital costs and INA-CBG rates for stroke in Indonesia. *Pharmacy Education*, 24(3), 166–172. <https://doi.org/10.46542/pe.2024.243.166172>
- Midha, A., Dearden, S., & McCormack, R. (2015). EGFR mutation incidence in non-small-cell lung cancer: A systematic review and global map of mutation frequency. *Lung Cancer*, 88(3), 195–203. <https://doi.org/10.1016/j.lungcan.2015.03.020>
- Miszczyńska, K., Krzeczewski, B., & Stawska, J. (2023). Different attitudes towards estimating indirect costs of disease: The example of cancer. *Health Economics Review*, 13(1), 21. <https://doi.org/10.1177/22799036251326636>
- Myers, D. J. (2023). *Lung adenocarcinoma*. In StatPearls. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK519578/>
- National Cancer Institute. (2024). Non-small cell lung cancer treatment (PDQ®)—Health professional version. *National Cancer Institute*. https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq#cit/section_1.1
- National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Small Cell Lung Cancer. Version 4. 2024. *JNCCN—Journal of the National Comprehensive Cancer Network*, 22(4), 249–274. <https://doi.org/10.6004/jnccn.2204.0023>

- National Comprehensive Cancer Network. (2024a). NCCN guidelines for patients®: Early and locally advanced non-small cell lung cancer (Version 7.2024). *NCCN*. <https://www.nccn.org/patientguidelines>
- National Comprehensive Cancer Network. (2024b). NCCN guidelines for patients®: Metastatic non-small cell lung cancer (Version 7.2024). *NCCN*. <https://www.nccn.org/patientguidelines>
- Nilsson, J., Berglund, A., Bergström, S., Bergqvist, M., & Lambe, M. (2017). The role of comorbidity in the management and prognosis in non-small cell lung cancer: A population-based study. *Acta Oncologica*, 56(7), 949–956. <https://doi.org/10.1080/0284186X.2017.1324213>
- Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., Simo, G. V., Vansteenkiste, J., Peters, S., & on behalf of the ESMO Guidelines Committee. (2016). Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines For Diagnosis, Treatment and Follow-Up. *Annals of Oncology*, 27(Supplement 5), 1–27. <https://doi.org/10.1093/annonc/mdw326>
- Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., & Peters, S. (2018). Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, 29(Suppl 4), iv192–iv237. <https://doi.org/10.1093/annonc/mdy275>
- Purba, I., Ramadhani, F., & Isnawati, A. (2015). Ketepatan obat, dosis, dan potensi interaksi obat pada pasien kanker paru di Rumah Sakit X Jawa Barat periode 2019-2021. *Jurnal Sains Kefarmasian*, 1(2), 120–131. <https://jsk.ff.unmul.ac.id/index.php/JSK/article/view/401>
- Radziwon, P., Krzakowski, M., Kalinka, E., Zaucha, R., & Wysocki, P. (2020). Anemia in cancer patients — Expert Group recommendations. Revision 2020. *Hematologia*, 11(1), 1–11. https://journals.viamedica.pl/hematology_in_clinical_practice/article/view/69756
- Rakihara, R., & Hidayati, N. (2020). Perbandingan tarif INA-CBGs dengan biaya riil rumah sakit pada kasus persalinan di RSUD Kota Kendari. *Jurnal Administrasi Rumah Sakit Indonesia*, 6(2), 101–110. <https://doi.org/10.7454/arsi.v6i2.376>
- Reck, M., Remon, J., & Hellmann, M. D. (2022). First-line immunotherapy for non–small-cell lung cancer. *Journal of Clinical Oncology*, 40(6), 586–597. <https://doi.org/10.1200/JCO.21.01497>
- Riely, G. J., Yu, H. A., Camidge, D. R., Neal, J. W., dkk. (2024). Non–Small Cell Lung Cancer, Version 4. 2024, NCCN Clinical Practice Guidelines in Oncology. *JNCCN–Journal of the National Comprehensive Cancer Network*, 22(4), 249–274. <https://doi.org/10.6004/jnccn.2204.0023>
- Robot, R. Y., Durry, M. F., & Kairupan, C. F. (2021). Morfologi, patogenesis, dan imunoterapi kanker paru tipe adenokarsinoma. *Medical Scope Journal*, 3(1), 74–82. <https://doi.org/10.35790/msj.3.1.2021.33544>
- Rushton, L., Hutchings, S. J., Fortunato, L., Young, C., Belluachi, E., Gupta, R., & Brown, T. (2020). Occupational exposures and lung cancer: A

- comprehensive review. *International Journal of Environmental Research and Public Health*, 17(21). <https://doi.org/10.3390/ijerph17218197>
- Sari, S., Andayani, T. M., Endarti, D., & Widayati, K. (2022). Cost-effectiveness analysis of afatinib versus gefitinib in non-small cell lung cancer (NSCLC) with EGFR mutation in Indonesia. *Research Journal of Pharmacy and Technology*, 15(11), 4991–4997. <https://doi.org/10.52711/0974-360X.2022.00834>
- Satibi, S., Andayani, T. M., Endarti, D., Suwantara, I. P. T., & Agustini, N. P. D. (2019). Comparison of real cost versus the Indonesian Case Base Groups (INA-CBGs) tariff rates among patients of high-incidence cancers under the National Health Insurance scheme. *Asian Pacific Journal of Cancer Prevention*, 20(1), 117–122. <https://doi.org/10.31557/APJCP.2019.20.1.117>
- Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. *CA: A Cancer Journal for Clinicians*, 70(1), 7–30. <https://doi.org/10.3322/caac.21590>
- Skarayadi, O., Syarifuddin, Sa'id, D., & Vikasari, S. N. (2024). Cost of illness pasien kanker paru-paru rawat inap di rumah sakit di Bandung. *Journal of Current Pharmaceutical Sciences*, 7(2), Maret 2024. https://www.researchgate.net/publication/380293558_Cost_Of_Illness_in_Patients_With_Lung_Cancer_In_A_Hospital_in_Bandung
- Speer, R. M., Zhou, X., Volk, L. B., Liu, K. J., & Hudson, L. G. (2022). Arsenic and cancer: Evidence and mechanisms. *Advances in Pharmacology*, 96, 151–202. <https://doi.org/10.1016/bs.apha.2022.08.001>
- Stayner, L., dkk. (2017). Exposure–response analyses of asbestos and lung cancer. *Epidemiology / Occupational Medicine*. https://journals.lww.com/epidem/fulltext/2017/03000/exposure_response_analyses_of_asbestos_and_lung.19.aspx
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>
- Sutandyo, N., & Suratman, E. (2024). Non-small-cell lung carcinoma in women: A retrospective cohort study in Indonesia. *Acta Medica Indonesiana*, 56(1), 25–31. <https://www.actamedindones.org/index.php/ijim/article/view/795>
- Tahayneh, K., Idkedek, M., & Abu Akar, F. (2025). NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives. *Journal Of Clinical Medicine*, 14(3), 1025. <https://doi.org/10.3390/jcm14031025>
- Thomas, R., Jenkins, S., Eastwood, P. R., Lee, Y. C. G., & Singh, B. (2015). Physiology of breathlessness associated with pleural effusions. *Current Opinion in Pulmonary Medicine*, 21(4), 338–345. <https://doi.org/10.1097/MCP.0000000000000174>
- Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., & Fernandez-Llimos, F. (2021). Principles of pharmacoeconomic analysis: The case of pharmacist-led interventions. *Pharmacy Practice*, 19(1), 2302

- Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., WHO Panel. (2015). The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. *Journal of Thoracic Oncology*, 10(9), 1243–1260. <https://doi.org/10.1097/JTO.0000000000000630>
- Vadgama, V. K., & Gaekwad, V. L. (2019). Cost minimization analysis of generic and innovator formulations of antihypertensive drugs. *International Journal of Basic & Clinical Pharmacology*, 8(12), 2740–2744. https://www.researchgate.net/publication/337555681_Cost_minimization_analysis_of_generic_and_innovator_formulations_of_antihypertensive_drugs
- van Zandwijk, N., Frank, A. L., Reid, G., Røe, O. D., & Amos, C. I. (2024). Asbestos-related lung cancer: An underappreciated oncological issue. *Lung Cancer*, 194, 107861. <https://doi.org/10.1016/j.lungcan.2024.107861>
- Vilman, P., Clementsen, P. F., Colella, S., Siemsen, M., De Leyn, P., Dumonceau, J. M., Herth, F. J. F., Larghi, A., Vazquez-Sequeiros, E., Hassan, C., Crombag, L., Korevaar, D. A., Konge, L., & Annema, J. T. (2015). Combined endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). *European Respiratory Journal*, 46(1), 40–60. <https://doi.org/10.1183/09031936.00064515>
- Wang, Y., Pond, G., Gafni, A. J., Kong, C. Y., & Ellis, P. M. (2025). Cost disparities with age in the treatment of advanced non-small-cell lung cancer (NSCLC) in Ontario, Canada. *Current Oncology*, 32(3), 1652–1664. https://www.researchgate.net/publication/392633628_Cost_Disparities_with_Age_in_the_Treatment_of_Advanced_Non-Small-Cell_Lung_Cancer_NSCLC_in_Ontario_Canada
- Waterhouse, D., Li, I., Morrison, L., Emond, B., Lafeuille, M.-H., Hilt, A., Korsiak, J., Lefebvre, P., Vadagam, P., & Waters, D. (2025). Healthcare resource use, healthcare costs, and unmet needs among patients treated for EGFR-mutated advanced or metastatic non-small cell lung cancer. *Journal of Health Economics and Outcomes Research*, 12(2), 98–107. <https://doi.org/10.36469/001c.142771>
- Wika, W. A., Poespita, K. S. D. W., Ulyaziza, B. A., & Restyana, A. (2024). Analysis of real hospital cost on INA-CBGs rates for cesarean section patients. *Journal for Quality in Public Health*, 8(1), 23–31. <https://doi.org/10.30994/jqph.v7i2.495>
- Wisløff, T., Hagen, G., Hamidi, V., Movik, E., Klemp, M., & Olsen, J. A. (2014). Estimating QALY gains in applied studies: A review of cost-utility analyses published in 2010. *Pharmacoeconomics*, 32(4), 367–375. <https://pubmed.ncbi.nlm.nih.gov/24477679/>
- World Health Organization. (2022). *Global tuberculosis report 2022*. World Health Organization. <https://iris.who.int/handle/10665/363752>

- Wulandari, A., Monalisa, S., & Zaini, J. (2019). Analisis Biaya Kemoterapi Lini Pertama Pada Pasien Kanker Paru di Rumah Sakit Persahabatan Jakarta Timur Periode Tahun 2016. *Sainstech Farma Jurnal Ilmu Kefarmasian*, 12(2), 85–92. http://repository.istn.ac.id/2894/1/Dokumen%20SFJ_Analisis%20Biaya20Kemo-1-10.pdf
- Wu, T., Yang, F., Chan, W. W. L., Lam, C. L. K., & Wong, C. K. H. (2020). Healthcare utilization and direct medical cost in the years during and after cancer diagnosis in patients with type 2 diabetes mellitus. *Journal of Diabetes Investigation*, 11(6), 1661–1672. <https://doi.org/10.1111/jdi.13308>
- Xu, H., Li, Y., Du, S., Zhang, Q., Liu, A., Sun, J., & Ma, G. (2020). Cost–utility and cost–benefit analyses of school-based obesity prevention program. *BMC Public Health*, 20, 1608. https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-020-09718-x?utm_
- Yang, X., dkk. (2022). Global burden of lung cancer attributable to ambient fine particulate matter (PM_{2.5}), 1990–2019. *Environmental Research/ ScienceDirect*. <https://www.sciencedirect.com/science/article/pii/S0013935121013189>
- Yin, X., Xu, Y., Man, X., Liu, L., Jiang, Y., Zhao, L., & Cheng, W. (2019). Direct costs of both inpatient and outpatient care for all type cancers: The evidence from Beijing, China. *Cancer Medicine*, 8(6), 3250–3260. <https://doi.org/10.1002/cam4.2184>
- Yuliasuti, F., Andayani, T. M., Endarti, D., & Kristina, S. A. (2023). Breast, cervical, and lung cancer: A comparison of real healthcare costs and INA CBGs rates in the era of national health insurance. *Pharmacy Practice (Granada)*, 21(1), 2768. <https://doi.org/10.18549/PharmPract.2023.1.2768>
- Yuliasuti, F., Andayani, T. M., Endarti, D., & Kristina, S. A. (2024). Cost determinant of chemotherapy in breast, cervical, and lung cancer in the era of National Health Insurance. *Pharmacy Practice*.
- Zappa, C., & Mousa, S. A. (2016). Non-small cell lung cancer: Current treatment and future advances. *Translational Lung Cancer Research*, 5(3), 288–300. <https://doi.org/10.21037/tlcr.2016.06.07>
- Zhang, Y. L., Yuan, J. Q., Wang, K. F., Fu, X. H., Han, X. R., Threapleton, D. E., Mao, C. (2016). The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. *Oncotarget*, 7(48), 78985–78993. <https://doi.org/10.18632/oncotarget.12587>
- Zhao, Y., Feng, H.-M., Qu, J., Luo, X., Ma, W.-J., & Tian, J.-H. (2018). A systematic review of pharmacoeconomic guidelines. *Journal of Medical Economics*, 21(1), 85–96. <https://doi.org/10.1080/13696998.2017.1387118>